Additional file 1 of Understanding the barriers and facilitators of COVID-19 risk mitigation strategy adoption and COVID-19 vaccination in refugee settlements in Uganda: a qualitative study

Supplementary Material

Additional file 1 of “Take services to the people”: strategies to optimize uptake of PrEP and harm reduction services among people who inject drugs in Uganda

Additional file 1. In-depth interview guide

PreScreening Data and Other Characteristics of Partners HSV-2 Study Sites

*<p>2004 or 2005 census data.</p>**<p>From PEPFAR (http//<a href="http://www.pepfar.gov/" target="_blank">www.pepfar.gov/</a>): “National HIV-1 prevalence among adults aged 15–49” for each country listed.</p> ˆ<p>Clinical trial recruitment also extended to outlying districts with total population of 0.75–1.5 million persons.</p>#<p>Source of HIV-1 prevalence data: Kenya-reference <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001411#pone.0001411-Kenyan1" target="_blank">[23]</a>; Uganda–reference <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001411#pone.0001411-Ministry1" target="_blank">[7]</a>; Tanzania–reference <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001411#pone.0001411-Kapiga1" target="_blank">[24]</a>; S. Africa–reference <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001411#pone.0001411-Dorrington1" target="_blank">[25]</a>; Zambia–reference <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001411#pone.0001411-Zambia1" target="_blank">[26]</a>; Botswana–reference <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001411#pone.0001411-UN2" target="_blank">[27]</a>.</p>&<p>-Total number of couples receiving HIV counseling and testing during previously defined recruitment periods: July 2005–April 2006 (Ndola and Kitwe, Zambia) and December 2006–April 2007 (all other Partners HSV-2 Study sites).</p>@<p>-NHRI calculated from PEPFAR data (http//<a href="http://www.pepfar.gov/" target="_blank">www.pepfar.gov/</a>) as: (“# individuals receiving counseling and testing in settings other than PMTCT in FY2006”+“# HIV-1 infected individuals receiving palliative care/basic health care and support in FY2006 (including HIV-1/TB)”)/“Adults and children (age 0–49) living with HIV-1 at the end of 2005”.</p

Distribution of components of the couples’ HIV-1 empiric risk score.

<p>Distribution of components of the couples’ HIV-1 empiric risk score.</p

Characteristics of the study subjects at enrollment (N = 1013 couples).

<p>Characteristics of the study subjects at enrollment (N = 1013 couples).</p

Screening, enrollment, and follow-up.

<p>Reasons for ineligibility are not mutually exclusive. A total of 1,013 higher-risk HIV-1-serodiscordant couples were enrolled. Of the initially HIV-1-seronegative partners, 12 subsequently seroconverted to HIV-1 but were found to have HIV-1 RNA in archived plasma from the time of enrollment, indicating acute seronegative HIV-1 infection.</p

Couple ART and PrEP use over time.

<p>This graph illustrates the overall distribution of ART use by HIV-1-infected partners and PrEP use by HIV-1-uninfected partners within the study partnerships, over follow-up. The proportion of couples using only PrEP for HIV-1 prevention declined over time, as HIV-1-infected participants initiated ART, as defined by the PrEP as a bridge to ART approach of the project. Through month 6, there was the greatest overlap between ART and PrEP; thereafter, couples with HIV-1 infected partners that initiated ART at or soon after enrollment begin to discontinue PrEP. The primary reason for couples using neither ART nor PrEP was missed visits, which were considered as not exposed to PrEP (since PrEP was distributed only at the study sites during the study period) nor to ART (which was assumed to have not been initiated until first reported).</p

HIV-1 incidence, expected versus observed.

<p>Expected HIV-1 incidence was estimated from a counterfactual model, bootstrapping data from a comparable at-risk population of HIV-1-serodiscordant couples. The graphic presents results for the entire study population. The table details the overall population estimates as well as analyses stratified by gender of the HIV-1-uninfected partner and baseline plasma HIV-1 RNA concentrations of the HIV-1-infected partner.</p

Baseline Characteristics of Enrolled HIV-1 Serodiscordant Couples (N = 4758).

<p>*Any contraceptive use includes: oral, injectable and implantable contraceptives, intrauterine device, hysterectomy or bilateral tubal ligation.</p><p>**Data on sexually transmitted infections available from a subset of participants.</p

Study Schema.

<p>Study Schema.</p